We believe the proposed dual‐ion delivery strategy could serve as an approach for cGAS‐STING mediated tumor immunotherapy, especially rescuing mutp53‐driven tumors and expanding the applications of ion intervention therapy. Here, STING1 is linked to neoplasm.